

Coronavirus Update for DC Employees: Talking Points for Leaders

McKesson's response to the Coronavirus:

- Since the virus was first identified, McKesson has been closely monitoring the rapidly evolving situation around the COVID-19 virus and is taking the steps necessary to protect our customers and ensure the safety of our employees.
- We are very aware of our important role in the health care system and are in close contact with regulatory authorities in Canada and around the world to ensure that we are equipped to address our customers' evolving needs, so that they can best care for their patients.
- We are working in collaboration with manufacturer partners to monitor and assess the potential impact to their pharmaceutical supply chains and are actively mitigating potential disruptions where possible.
- As it relates to the inventory of Personal Safety Devices (masks/gloves, hand sanitizer, wipes, etc.), we have put filters in place, increased our orders and are working with manufacturers to expedite deliveries. We are also looking to source new products from alternate suppliers where possible and have already been successful in some cases (i.e. sanitizer new listing, etc.).
- McKesson has robust business continuity plans (BCP's), which are ready to be put into action if needed - should a DC become affected, we would transfer products and resources to another DC, and, if necessary, prioritize Rx/OTC over Front Shop items.

Level-2 Canadian update:

- Canada recently confirmed its first case of "community spread" - a person-to-person transmission that is not travel-related.
- Given these developments, we are taking the following steps to protect the health, safety and wellbeing of the McKesson community, while protecting the integrity of our supply chains and the critical support we provide our patients and customers:
 - We are restricting all non-essential travel for Canadian employees both at the international and domestic level. This is in addition to the Corporation's current restrictions on all non-essential travel to / from Europe, China, South Korea, Italy, Iran, and affected areas in the US.
 - Employees must receive approval from their Senior Vice-President for travel in essential or exceptional circumstances.
- We are postponing all McKesson-led corporate meetings and events (greater than 25 people) until June 1, 2020. This includes internal and external corporate events, conferences and tradeshows. We are keeping our event participants informed as the situation progresses.

-
- We encourage employees who do not have to be onsite to perform their roles to work from home and telecommute on a voluntary basis.
 - For those who must report to work to continue operations (for example: DC, INVIVA, retail operations employees), we continue to work to ensure a safe working environment.
 - If you are unsure what category your role falls into, please reach out to your leader.
 - Regardless of your work arrangement, our top priority is to protect the health of every McKesson employee and maintain safe work environments for all.

Potential drug shortages:

- At this time, Health Canada is not aware of any impact of the novel coronavirus outbreak in China on Canada's pharmaceutical supply.
- The Department has engaged pharmaceutical industry stakeholders to seek any early signals that may indicate impacts on the drug supply chain, and none have been reported to date.
- McKesson Canada is also engaging with importers who may have links to foreign sites in the portions of China most severely affected.
- We continue to analyze signals as they are brought to our attention but have not identified any concrete impacts.
- The Department will continue monitoring the situation closely and will take action if needed, in collaboration with companies, the provinces and territories and other stakeholders, to mitigate any impact on patients.
- Health Canada is also engaged with other international regulators to monitor any impacts on global supply.